WallStreetZenWallStreetZen

NASDAQ: ORIC
Oric Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for ORIC

Based on 6 analysts offering 12 month price targets for Oric Pharmaceuticals Inc.
Min Forecast
$14.00+55.73%
Avg Forecast
$19.17+113.2%
Max Forecast
$25.00+178.09%

Should I buy or sell ORIC stock?

Based on 6 analysts offering ratings for Oric Pharmaceuticals Inc.
Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ORIC stock forecasts and price targets.

ORIC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-21
lockedlocked$00.00+00.00%2024-03-12
lockedlocked$00.00+00.00%2024-03-12
Baird
Bottom 3%
3
BuyReiterates$25.00+178.09%2024-03-12

1 of 1

Forecast return on equity

Is ORIC forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.86%

Forecast return on assets

Is ORIC forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ORIC revenue forecast

What is ORIC's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$20.5M
Avg 2 year Forecast
$164.8M
Avg 3 year Forecast
$436.7M

ORIC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ORIC$8.99$19.17+113.20%Strong Buy
ITOS$16.74$36.50+118.04%Strong Buy
HLVX$12.14$26.00+114.17%Strong Buy
ZYME$8.48$12.67+49.38%Strong Buy
PHAR$9.15$37.00+304.37%Buy

Oric Pharmaceuticals Stock Forecast FAQ

Is Oric Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ORIC) stock is to Strong Buy ORIC stock.

Out of 6 analysts, 2 (33.33%) are recommending ORIC as a Strong Buy, 4 (66.67%) are recommending ORIC as a Buy, 0 (0%) are recommending ORIC as a Hold, 0 (0%) are recommending ORIC as a Sell, and 0 (0%) are recommending ORIC as a Strong Sell.

If you're new to stock investing, here's how to buy Oric Pharmaceuticals stock.

What is ORIC's revenue growth forecast for 2026-2028?

(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Oric Pharmaceuticals's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2026 to be $1,383,977,696, with the lowest ORIC revenue forecast at $191,142,240, and the highest ORIC revenue forecast at $2,576,880,574. On average, 1 Wall Street analysts forecast ORIC's revenue for 2027 to be $11,113,218,863, with the lowest ORIC revenue forecast at $11,113,218,863, and the highest ORIC revenue forecast at $11,113,218,863.

In 2028, ORIC is forecast to generate $29,442,647,244 in revenue, with the lowest revenue forecast at $29,442,647,244 and the highest revenue forecast at $29,442,647,244.

What is ORIC's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ORIC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ORIC's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ORIC price target, the average ORIC price target is $19.17, with the highest ORIC stock price forecast at $25.00 and the lowest ORIC stock price forecast at $14.00.

On average, Wall Street analysts predict that Oric Pharmaceuticals's share price could reach $19.17 by May 7, 2025. The average Oric Pharmaceuticals stock price prediction forecasts a potential upside of 113.2% from the current ORIC share price of $8.99.

What is ORIC's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ORIC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.